Lujo virus (LUJV) is a new viral pathogen discovered in South Africa during a nosocomial viral hemorrhagic fever (VHF) outbreak in September-October 2008. The outbreak involved a small group of five individuals and had an 80% case fatality rate, which signifies those four of the five cases led to death.
This high mortality rate sets LUJV apart from other arenaviruses, like the Lassa virus (LASV), which generally have lower case fatality rates. The identification of LUJV marked the first discovery of a new arenavirus in over 40 years.
Patient 1, the index case, infected three healthcare personnel, causing secondary transmission inside the healthcare context. A fourth healthcare worker survived the virus after receiving ribavirin treatment.
The patients had a clinical condition that resembled a severe and fulminant LASV infection, with fast deterioration, respiratory distress, neurological abnormalities, and circulatory concerns that led to a collapse. Death happened within 10-15 days of the commencement of symptoms.
LUJV is classified as an Old-World arenavirus and shares similarities with other members of the arenavirus family. It is an enveloped virus with a segmented, single-stranded, negative-sense RNA genome. The G1 glycoprotein of LUJV was found to be genetically distinct from other known arenaviruses, indicating its novelty.
The natural reservoir of LUJV remains unknown, but rodents are suspected to be the hosts. The affected patients had various backgrounds and occupations, including individuals from Zambia and South Africa. Patient 1 had a potential rodent exposure in her agricultural smallholding, while healthcare workers involved in the care of patient 1 were also affected, suggesting nosocomial transmission.
Kingdom: Virus
Phylum: Negarnaviricota
Class: Ellioviricetes
Order: Bunyavirales
Family: Arenaviridae
Genus:Mammarenavirus
Species:Lujo virus
LUJV is enveloped; a lipid bilayer membrane surrounds it. The envelope gives the virus its spherical shape and protects its genetic material.Its diameter is about 100 nanometers, making it tiny compared to other arenavirus viruses.LUJV‘s RNA genome is encased in a helical nucleocapsid structure. The nucleocapsid is generated when the viral RNA & the nucleoprotein (NP) interact.
The RNA genome of LUJV is bi-segmented, with two different RNA segments known as the large segment (L) & the small segment (S). These segments encode many viral proteins that are required for replication & infection.
The LUJV viral envelope comprises glycoprotein spikes. These spikes comprise the glycoprotein precursor (GPC), broken down into two subunits, GP1 & GP2.LUJV possesses a small matrix protein (Z) encoded by the S segment.
Lujo virus (LUJV) has distinct structural characteristics and genetic motifs that assist in its virulence and potential antigenic qualities. The LUJV transmembrane (TM) domain, notably amino acid residue C410, is critical for membrane fusion & receptor tropism. This positional mutation, like the C410G variation, can affect viral entrance and replication.
The glycoproteins of LUJV also have different structural features. The receptor-binding subunit GP1 possesses an extended N-terminal region that may alter its interaction with host receptors, possibly contributing to receptor tropism differences. The fusion protein subunit GP2 has a larger transmembrane domain, which may interfere with virus-host cell membrane fusion.
Within LUJV proteins, several amino acid motifs have been found. The Y77REL motif identified in LUJV is distinctive and may have a role in viral proliferation and pathogenesis. Furthermore, the LUJV NP gene encodes the nucleoprotein, which comprises described amino acid patterns such as G122VYRGNL. These motifs could have a role in viral replication and interactions with host components.
P90SAP, a Tsg101-interacting motif found in LUJV, may have a role in viral assembly & release, comparable to the second late domain of LASV. Furthermore, a putative antigenic site in LUJV, particularly the R55KDKRND motif, has been identified, which could contribute to the virus’s ability to induce an immunological response.
Several studies have discovered host genes that may play a role in Lujo virus pathogenesis or vulnerability. These include TMEM30A (also referred to as CDC50A), NRP2, & CD63, all of which have been linked to greater vulnerability to viral infections in general. TMEM30A participates in phospholipid translocation.
Hence, its mutation may influence cellular processes involved in viral replication or immune response. NRP2 and CD63 are involved in various physiological processes, notably cell adhesion; thus, endocytosis and mutations in these domains may influence viral entrance or host immunological responses.
Lujo virus (LUJV) is an arenavirus with a rodent host as its natural reservoir. Humans can catch Lujo Hemorrhagic Fever (LUHF) by directly contacting diseased rats or inhaling aerosolized virus particles from contaminated rodent urine or feces. The primary transmission mode within the human population is person-to-person, as observed in the nosocomial cluster of hemorrhagic disease during the outbreak.
A genome-wide haploid genetics analysis identified tetraspanin CD63 & neuropilin 2 (NRP2) as LUJV GP-mediated infection factors. LUJV GP binds the N-terminal region of NRP2, and CD63 enhances pH-activated LUJV GP-mediated fusion of the membrane.
The entry of the Lujo virus into host cells involves its binding to specific receptors on the cell surface. While α-dystroglycan is the central receptor for Old World arenaviruses like LUJV, the primary receptor for New World arenaviruses is the human transferrin receptor 1.
Following receptor binding, the virus is internalized into the host cell cytoplasm via endocytosis. The release of viral ribonucleoprotein inside the infected cell triggers viral RNA replication and gene transcription. The virus replicates and spreads within the host, leading to systemic infection.
It has been discovered that LUJV‘s matrix protein (Z) & glycoprotein precursor play critical roles in viral release. The L domain, a short amino acid motif found in Z, interacts with biological components to mediate viral particle budding, allowing freshly produced viral particles to be released from infected cells.
Notably, the cellular factors necessary for LUJV budding differed from those required for LASV budding. Furthermore, the GPC protein is cleaved by site 1 protease. A reduction in LUJV formation was seen in tests utilizing an S1P inhibitors (PF-429242), showing the potential as a therapeutic target.
LUJV infection causes a solid immunological response that includes the generation of proinflammatory cytokines & interferon-alpha/beta (IFN-I). Elevated levels of IFN-I & cytokines have been linked to illness severity. Several host variables and pathways are involved in the immune system’s detection of LUJV.
By recognizing viral RNA structures such as double-stranded RNA (dsRNA) and stem-loops, the cytosolic patterns recognition receptors (PRRs), retinoic acid-inducible genes I (RIG-I), and melanoma differentiation-associated protein 5 (MDA-5) detect LUJV infection.
When RIG-I and MDA-5 are activated, IFN-I and transcription factors that uphands the expression of genes stimulated by interferon (ISGs) with antiviral activity are produced. RIG-I & MDA-5 have been demonstrated to be upregulated in response to LUJV infection, & their colocalization through viral nucleoprotein (NP) suggests an immediate link with their participation in the antiviral response.
The protein kinase R (PKR), which detects viral dsRNA & becomes activated, is another host component involved in the immunological response to LUJV. When the PKR is activated, it phosphorylates translation initiation factor eIF2, resulting in global host translation shutdown and the antiviral IFN-I response regulation.
Different LUJV strains interact with PKR in different ways, with some strains generating substantial PKR activation & translation suppression. The significance of PKR in LUJV infection management and its interaction with other immunological variables requires further investigation.
The interaction between secreted IFN-I & its receptor (IFNAR) promotes downstream signaling pathways that stimulate the production of ISGs. LUJV infection causes an increase in the expression of several ISGs, including ISG15, viperin, & BST-2. ISG15 contributes to antiviral defense, but viperin and BST-2 limit viral release from infected cells.
The NP and Z proteins of LUJV have been linked to IFN-I response modulation. IRF-3 & NF-κB nuclear translocation can be inhibited by NP, lowering IFN- promoter activity. It may also inhibit RIG-I function & inhibit IFN-β generation. Z protein interacts directly with RIG-I and MDA-5, limiting their interaction with downstream signaling pathways & inhibiting NF-κB & IRF-3 activation.
Lujo virus (LUJV) infection causes Lujo hemorrhagic fever (LUHF), characterized by manifestations like severe Lassa fever caused by another arenavirus. The onset of the illness is sudden, with nonspecific symptoms such as fever, malaise, headache, and muscle pain. Additional symptoms follow it, including sore throat, nausea, vomiting, non-bloody diarrhea, and variable retrosternal or epigastric pain.
During the first week of illness, a distinctive rash appears on the torso and limbs. The rash is blanching, erythematous, and maculopapular, spreading across the body but sparing the palms and soles. Facial swelling with subconjunctival hemorrhage is also commonly observed.
Neurologic signs tend to occur later in the disease course, including tremors, seizures, and cerebral edema. Hepatosplenomegaly, or enlargement of the liver and spleen, may develop. While significant bleeding is not typically seen, subconjunctival hemorrhages, palatal ecchymoses, and bleeding at injection sites may occur.
The disease rapidly progresses to multiorgan failure and shock in the second week of illness. Disseminated intravascular coagulopathy may be present, characterized by abnormal blood clotting and bleeding. Neurological complications can also manifest in the later stages of the disease.
The case fatality rate of Lujo virus infection is extremely high, ranging from 80% to 100%. Most deaths occur within a mean of 9 days from the onset of symptoms, although the survivor may experience a prolonged recovery.
A series of laboratory tests on blood samples, liver biopsies, & skin pinch biopsies from patients 3 and 2 were used to diagnose the Lujo virus. Initially, the National Institute for Communicable Disease (NICD-NHLS) in Johannesburg performed reverse transcription-polymerase chain reaction (RT-PCR), antigen detection enzyme-linked immunosorbent tests (ELISA), and antibody detection ELISA.
These assays detect known agents of African viral hemorrhagic fevers, such as the Lassa Fever Virus and other arenaviruses from the Old World (OW). All tests, however, had negative results.
To further study the cases, liver and skin biopsy samples were collected from the patients at the NICD’s biosafety level four facility. While these biopsies were tested in South Africa, tissues were shipped to the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, and to Columbia University in New York. The University of the Witwatersrand’s Department of Anatomical Pathology found histopathological results confirming viral hemorrhagic fever in liver & skin biopsies.
Immunohistochemical staining: It detects Lujo virus antigens in tissue samples like liver and skin biopsies. Monoclonal antibodies, for example, are broadly cross-reactive with Old World arenaviruses, including the Lujo virus.
This antibody binds selectively to Lujo virus antigens found in tissue sections. The antibody is frequently labeled with a visible marker, like an enzyme or fluorescent dye, so the stained spots may be seen under a microscope. The appearance and distribution of Lujo virus antigens in tissue slices can be recognized by staining, confirming the existence of Lujo virus infection.
Antibody Detection ELISA: This test detects the presence of antibodies produced by the patient’s immune system in response to the Lujo virus infection. It can identify IgM antibodies, indicating recent or acute infection, or IgG antibodies, indicating past or previous infection.
Genetic Sequencing: In-depth genetic sequencing techniques, such as 454-pyrosequencing, can be employed to determine the complete genome sequence of the Lujo virus. It provides valuable information about the virus’s genetic makeup, allowing for further characterization and comparison with related viruses.
Preventing exposure to rodents and their excrement, implementing infection control practices in healthcare settings.
Early diagnosis and treatment may improve outcomes. Ribavirin has been used, but its efficacy is uncertain. Other potential treatments being explored include statins, N-acetylcysteine, and recombinant factor VIIa, but more research is needed to confirm their effectiveness.
Currently, there is no specific vaccine for the Lujo virus. Some studies have identified potential Lujo virus entry inhibitors, which may lead to vaccine development. Drugs such as trametinib, manidipine, and lercanidipine have shown potential as inhibitors, but further studies are required to evaluate their antiviral activity and mode of action in vivo.
Lujo virus (LUJV) is a new viral pathogen discovered in South Africa during a nosocomial viral hemorrhagic fever (VHF) outbreak in September-October 2008. The outbreak involved a small group of five individuals and had an 80% case fatality rate, which signifies those four of the five cases led to death.
This high mortality rate sets LUJV apart from other arenaviruses, like the Lassa virus (LASV), which generally have lower case fatality rates. The identification of LUJV marked the first discovery of a new arenavirus in over 40 years.
Patient 1, the index case, infected three healthcare personnel, causing secondary transmission inside the healthcare context. A fourth healthcare worker survived the virus after receiving ribavirin treatment.
The patients had a clinical condition that resembled a severe and fulminant LASV infection, with fast deterioration, respiratory distress, neurological abnormalities, and circulatory concerns that led to a collapse. Death happened within 10-15 days of the commencement of symptoms.
LUJV is classified as an Old-World arenavirus and shares similarities with other members of the arenavirus family. It is an enveloped virus with a segmented, single-stranded, negative-sense RNA genome. The G1 glycoprotein of LUJV was found to be genetically distinct from other known arenaviruses, indicating its novelty.
The natural reservoir of LUJV remains unknown, but rodents are suspected to be the hosts. The affected patients had various backgrounds and occupations, including individuals from Zambia and South Africa. Patient 1 had a potential rodent exposure in her agricultural smallholding, while healthcare workers involved in the care of patient 1 were also affected, suggesting nosocomial transmission.
Kingdom: Virus
Phylum: Negarnaviricota
Class: Ellioviricetes
Order: Bunyavirales
Family: Arenaviridae
Genus:Mammarenavirus
Species:Lujo virus
LUJV is enveloped; a lipid bilayer membrane surrounds it. The envelope gives the virus its spherical shape and protects its genetic material.Its diameter is about 100 nanometers, making it tiny compared to other arenavirus viruses.LUJV‘s RNA genome is encased in a helical nucleocapsid structure. The nucleocapsid is generated when the viral RNA & the nucleoprotein (NP) interact.
The RNA genome of LUJV is bi-segmented, with two different RNA segments known as the large segment (L) & the small segment (S). These segments encode many viral proteins that are required for replication & infection.
The LUJV viral envelope comprises glycoprotein spikes. These spikes comprise the glycoprotein precursor (GPC), broken down into two subunits, GP1 & GP2.LUJV possesses a small matrix protein (Z) encoded by the S segment.
Lujo virus (LUJV) has distinct structural characteristics and genetic motifs that assist in its virulence and potential antigenic qualities. The LUJV transmembrane (TM) domain, notably amino acid residue C410, is critical for membrane fusion & receptor tropism. This positional mutation, like the C410G variation, can affect viral entrance and replication.
The glycoproteins of LUJV also have different structural features. The receptor-binding subunit GP1 possesses an extended N-terminal region that may alter its interaction with host receptors, possibly contributing to receptor tropism differences. The fusion protein subunit GP2 has a larger transmembrane domain, which may interfere with virus-host cell membrane fusion.
Within LUJV proteins, several amino acid motifs have been found. The Y77REL motif identified in LUJV is distinctive and may have a role in viral proliferation and pathogenesis. Furthermore, the LUJV NP gene encodes the nucleoprotein, which comprises described amino acid patterns such as G122VYRGNL. These motifs could have a role in viral replication and interactions with host components.
P90SAP, a Tsg101-interacting motif found in LUJV, may have a role in viral assembly & release, comparable to the second late domain of LASV. Furthermore, a putative antigenic site in LUJV, particularly the R55KDKRND motif, has been identified, which could contribute to the virus’s ability to induce an immunological response.
Several studies have discovered host genes that may play a role in Lujo virus pathogenesis or vulnerability. These include TMEM30A (also referred to as CDC50A), NRP2, & CD63, all of which have been linked to greater vulnerability to viral infections in general. TMEM30A participates in phospholipid translocation.
Hence, its mutation may influence cellular processes involved in viral replication or immune response. NRP2 and CD63 are involved in various physiological processes, notably cell adhesion; thus, endocytosis and mutations in these domains may influence viral entrance or host immunological responses.
Lujo virus (LUJV) is an arenavirus with a rodent host as its natural reservoir. Humans can catch Lujo Hemorrhagic Fever (LUHF) by directly contacting diseased rats or inhaling aerosolized virus particles from contaminated rodent urine or feces. The primary transmission mode within the human population is person-to-person, as observed in the nosocomial cluster of hemorrhagic disease during the outbreak.
A genome-wide haploid genetics analysis identified tetraspanin CD63 & neuropilin 2 (NRP2) as LUJV GP-mediated infection factors. LUJV GP binds the N-terminal region of NRP2, and CD63 enhances pH-activated LUJV GP-mediated fusion of the membrane.
The entry of the Lujo virus into host cells involves its binding to specific receptors on the cell surface. While α-dystroglycan is the central receptor for Old World arenaviruses like LUJV, the primary receptor for New World arenaviruses is the human transferrin receptor 1.
Following receptor binding, the virus is internalized into the host cell cytoplasm via endocytosis. The release of viral ribonucleoprotein inside the infected cell triggers viral RNA replication and gene transcription. The virus replicates and spreads within the host, leading to systemic infection.
It has been discovered that LUJV‘s matrix protein (Z) & glycoprotein precursor play critical roles in viral release. The L domain, a short amino acid motif found in Z, interacts with biological components to mediate viral particle budding, allowing freshly produced viral particles to be released from infected cells.
Notably, the cellular factors necessary for LUJV budding differed from those required for LASV budding. Furthermore, the GPC protein is cleaved by site 1 protease. A reduction in LUJV formation was seen in tests utilizing an S1P inhibitors (PF-429242), showing the potential as a therapeutic target.
LUJV infection causes a solid immunological response that includes the generation of proinflammatory cytokines & interferon-alpha/beta (IFN-I). Elevated levels of IFN-I & cytokines have been linked to illness severity. Several host variables and pathways are involved in the immune system’s detection of LUJV.
By recognizing viral RNA structures such as double-stranded RNA (dsRNA) and stem-loops, the cytosolic patterns recognition receptors (PRRs), retinoic acid-inducible genes I (RIG-I), and melanoma differentiation-associated protein 5 (MDA-5) detect LUJV infection.
When RIG-I and MDA-5 are activated, IFN-I and transcription factors that uphands the expression of genes stimulated by interferon (ISGs) with antiviral activity are produced. RIG-I & MDA-5 have been demonstrated to be upregulated in response to LUJV infection, & their colocalization through viral nucleoprotein (NP) suggests an immediate link with their participation in the antiviral response.
The protein kinase R (PKR), which detects viral dsRNA & becomes activated, is another host component involved in the immunological response to LUJV. When the PKR is activated, it phosphorylates translation initiation factor eIF2, resulting in global host translation shutdown and the antiviral IFN-I response regulation.
Different LUJV strains interact with PKR in different ways, with some strains generating substantial PKR activation & translation suppression. The significance of PKR in LUJV infection management and its interaction with other immunological variables requires further investigation.
The interaction between secreted IFN-I & its receptor (IFNAR) promotes downstream signaling pathways that stimulate the production of ISGs. LUJV infection causes an increase in the expression of several ISGs, including ISG15, viperin, & BST-2. ISG15 contributes to antiviral defense, but viperin and BST-2 limit viral release from infected cells.
The NP and Z proteins of LUJV have been linked to IFN-I response modulation. IRF-3 & NF-κB nuclear translocation can be inhibited by NP, lowering IFN- promoter activity. It may also inhibit RIG-I function & inhibit IFN-β generation. Z protein interacts directly with RIG-I and MDA-5, limiting their interaction with downstream signaling pathways & inhibiting NF-κB & IRF-3 activation.
Lujo virus (LUJV) infection causes Lujo hemorrhagic fever (LUHF), characterized by manifestations like severe Lassa fever caused by another arenavirus. The onset of the illness is sudden, with nonspecific symptoms such as fever, malaise, headache, and muscle pain. Additional symptoms follow it, including sore throat, nausea, vomiting, non-bloody diarrhea, and variable retrosternal or epigastric pain.
During the first week of illness, a distinctive rash appears on the torso and limbs. The rash is blanching, erythematous, and maculopapular, spreading across the body but sparing the palms and soles. Facial swelling with subconjunctival hemorrhage is also commonly observed.
Neurologic signs tend to occur later in the disease course, including tremors, seizures, and cerebral edema. Hepatosplenomegaly, or enlargement of the liver and spleen, may develop. While significant bleeding is not typically seen, subconjunctival hemorrhages, palatal ecchymoses, and bleeding at injection sites may occur.
The disease rapidly progresses to multiorgan failure and shock in the second week of illness. Disseminated intravascular coagulopathy may be present, characterized by abnormal blood clotting and bleeding. Neurological complications can also manifest in the later stages of the disease.
The case fatality rate of Lujo virus infection is extremely high, ranging from 80% to 100%. Most deaths occur within a mean of 9 days from the onset of symptoms, although the survivor may experience a prolonged recovery.
A series of laboratory tests on blood samples, liver biopsies, & skin pinch biopsies from patients 3 and 2 were used to diagnose the Lujo virus. Initially, the National Institute for Communicable Disease (NICD-NHLS) in Johannesburg performed reverse transcription-polymerase chain reaction (RT-PCR), antigen detection enzyme-linked immunosorbent tests (ELISA), and antibody detection ELISA.
These assays detect known agents of African viral hemorrhagic fevers, such as the Lassa Fever Virus and other arenaviruses from the Old World (OW). All tests, however, had negative results.
To further study the cases, liver and skin biopsy samples were collected from the patients at the NICD’s biosafety level four facility. While these biopsies were tested in South Africa, tissues were shipped to the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, and to Columbia University in New York. The University of the Witwatersrand’s Department of Anatomical Pathology found histopathological results confirming viral hemorrhagic fever in liver & skin biopsies.
Immunohistochemical staining: It detects Lujo virus antigens in tissue samples like liver and skin biopsies. Monoclonal antibodies, for example, are broadly cross-reactive with Old World arenaviruses, including the Lujo virus.
This antibody binds selectively to Lujo virus antigens found in tissue sections. The antibody is frequently labeled with a visible marker, like an enzyme or fluorescent dye, so the stained spots may be seen under a microscope. The appearance and distribution of Lujo virus antigens in tissue slices can be recognized by staining, confirming the existence of Lujo virus infection.
Antibody Detection ELISA: This test detects the presence of antibodies produced by the patient’s immune system in response to the Lujo virus infection. It can identify IgM antibodies, indicating recent or acute infection, or IgG antibodies, indicating past or previous infection.
Genetic Sequencing: In-depth genetic sequencing techniques, such as 454-pyrosequencing, can be employed to determine the complete genome sequence of the Lujo virus. It provides valuable information about the virus’s genetic makeup, allowing for further characterization and comparison with related viruses.
Preventing exposure to rodents and their excrement, implementing infection control practices in healthcare settings.
Early diagnosis and treatment may improve outcomes. Ribavirin has been used, but its efficacy is uncertain. Other potential treatments being explored include statins, N-acetylcysteine, and recombinant factor VIIa, but more research is needed to confirm their effectiveness.
Currently, there is no specific vaccine for the Lujo virus. Some studies have identified potential Lujo virus entry inhibitors, which may lead to vaccine development. Drugs such as trametinib, manidipine, and lercanidipine have shown potential as inhibitors, but further studies are required to evaluate their antiviral activity and mode of action in vivo.
Lujo virus (LUJV) is a new viral pathogen discovered in South Africa during a nosocomial viral hemorrhagic fever (VHF) outbreak in September-October 2008. The outbreak involved a small group of five individuals and had an 80% case fatality rate, which signifies those four of the five cases led to death.
This high mortality rate sets LUJV apart from other arenaviruses, like the Lassa virus (LASV), which generally have lower case fatality rates. The identification of LUJV marked the first discovery of a new arenavirus in over 40 years.
Patient 1, the index case, infected three healthcare personnel, causing secondary transmission inside the healthcare context. A fourth healthcare worker survived the virus after receiving ribavirin treatment.
The patients had a clinical condition that resembled a severe and fulminant LASV infection, with fast deterioration, respiratory distress, neurological abnormalities, and circulatory concerns that led to a collapse. Death happened within 10-15 days of the commencement of symptoms.
LUJV is classified as an Old-World arenavirus and shares similarities with other members of the arenavirus family. It is an enveloped virus with a segmented, single-stranded, negative-sense RNA genome. The G1 glycoprotein of LUJV was found to be genetically distinct from other known arenaviruses, indicating its novelty.
The natural reservoir of LUJV remains unknown, but rodents are suspected to be the hosts. The affected patients had various backgrounds and occupations, including individuals from Zambia and South Africa. Patient 1 had a potential rodent exposure in her agricultural smallholding, while healthcare workers involved in the care of patient 1 were also affected, suggesting nosocomial transmission.
Kingdom: Virus
Phylum: Negarnaviricota
Class: Ellioviricetes
Order: Bunyavirales
Family: Arenaviridae
Genus:Mammarenavirus
Species:Lujo virus
LUJV is enveloped; a lipid bilayer membrane surrounds it. The envelope gives the virus its spherical shape and protects its genetic material.Its diameter is about 100 nanometers, making it tiny compared to other arenavirus viruses.LUJV‘s RNA genome is encased in a helical nucleocapsid structure. The nucleocapsid is generated when the viral RNA & the nucleoprotein (NP) interact.
The RNA genome of LUJV is bi-segmented, with two different RNA segments known as the large segment (L) & the small segment (S). These segments encode many viral proteins that are required for replication & infection.
The LUJV viral envelope comprises glycoprotein spikes. These spikes comprise the glycoprotein precursor (GPC), broken down into two subunits, GP1 & GP2.LUJV possesses a small matrix protein (Z) encoded by the S segment.
Lujo virus (LUJV) has distinct structural characteristics and genetic motifs that assist in its virulence and potential antigenic qualities. The LUJV transmembrane (TM) domain, notably amino acid residue C410, is critical for membrane fusion & receptor tropism. This positional mutation, like the C410G variation, can affect viral entrance and replication.
The glycoproteins of LUJV also have different structural features. The receptor-binding subunit GP1 possesses an extended N-terminal region that may alter its interaction with host receptors, possibly contributing to receptor tropism differences. The fusion protein subunit GP2 has a larger transmembrane domain, which may interfere with virus-host cell membrane fusion.
Within LUJV proteins, several amino acid motifs have been found. The Y77REL motif identified in LUJV is distinctive and may have a role in viral proliferation and pathogenesis. Furthermore, the LUJV NP gene encodes the nucleoprotein, which comprises described amino acid patterns such as G122VYRGNL. These motifs could have a role in viral replication and interactions with host components.
P90SAP, a Tsg101-interacting motif found in LUJV, may have a role in viral assembly & release, comparable to the second late domain of LASV. Furthermore, a putative antigenic site in LUJV, particularly the R55KDKRND motif, has been identified, which could contribute to the virus’s ability to induce an immunological response.
Several studies have discovered host genes that may play a role in Lujo virus pathogenesis or vulnerability. These include TMEM30A (also referred to as CDC50A), NRP2, & CD63, all of which have been linked to greater vulnerability to viral infections in general. TMEM30A participates in phospholipid translocation.
Hence, its mutation may influence cellular processes involved in viral replication or immune response. NRP2 and CD63 are involved in various physiological processes, notably cell adhesion; thus, endocytosis and mutations in these domains may influence viral entrance or host immunological responses.
Lujo virus (LUJV) is an arenavirus with a rodent host as its natural reservoir. Humans can catch Lujo Hemorrhagic Fever (LUHF) by directly contacting diseased rats or inhaling aerosolized virus particles from contaminated rodent urine or feces. The primary transmission mode within the human population is person-to-person, as observed in the nosocomial cluster of hemorrhagic disease during the outbreak.
A genome-wide haploid genetics analysis identified tetraspanin CD63 & neuropilin 2 (NRP2) as LUJV GP-mediated infection factors. LUJV GP binds the N-terminal region of NRP2, and CD63 enhances pH-activated LUJV GP-mediated fusion of the membrane.
The entry of the Lujo virus into host cells involves its binding to specific receptors on the cell surface. While α-dystroglycan is the central receptor for Old World arenaviruses like LUJV, the primary receptor for New World arenaviruses is the human transferrin receptor 1.
Following receptor binding, the virus is internalized into the host cell cytoplasm via endocytosis. The release of viral ribonucleoprotein inside the infected cell triggers viral RNA replication and gene transcription. The virus replicates and spreads within the host, leading to systemic infection.
It has been discovered that LUJV‘s matrix protein (Z) & glycoprotein precursor play critical roles in viral release. The L domain, a short amino acid motif found in Z, interacts with biological components to mediate viral particle budding, allowing freshly produced viral particles to be released from infected cells.
Notably, the cellular factors necessary for LUJV budding differed from those required for LASV budding. Furthermore, the GPC protein is cleaved by site 1 protease. A reduction in LUJV formation was seen in tests utilizing an S1P inhibitors (PF-429242), showing the potential as a therapeutic target.
LUJV infection causes a solid immunological response that includes the generation of proinflammatory cytokines & interferon-alpha/beta (IFN-I). Elevated levels of IFN-I & cytokines have been linked to illness severity. Several host variables and pathways are involved in the immune system’s detection of LUJV.
By recognizing viral RNA structures such as double-stranded RNA (dsRNA) and stem-loops, the cytosolic patterns recognition receptors (PRRs), retinoic acid-inducible genes I (RIG-I), and melanoma differentiation-associated protein 5 (MDA-5) detect LUJV infection.
When RIG-I and MDA-5 are activated, IFN-I and transcription factors that uphands the expression of genes stimulated by interferon (ISGs) with antiviral activity are produced. RIG-I & MDA-5 have been demonstrated to be upregulated in response to LUJV infection, & their colocalization through viral nucleoprotein (NP) suggests an immediate link with their participation in the antiviral response.
The protein kinase R (PKR), which detects viral dsRNA & becomes activated, is another host component involved in the immunological response to LUJV. When the PKR is activated, it phosphorylates translation initiation factor eIF2, resulting in global host translation shutdown and the antiviral IFN-I response regulation.
Different LUJV strains interact with PKR in different ways, with some strains generating substantial PKR activation & translation suppression. The significance of PKR in LUJV infection management and its interaction with other immunological variables requires further investigation.
The interaction between secreted IFN-I & its receptor (IFNAR) promotes downstream signaling pathways that stimulate the production of ISGs. LUJV infection causes an increase in the expression of several ISGs, including ISG15, viperin, & BST-2. ISG15 contributes to antiviral defense, but viperin and BST-2 limit viral release from infected cells.
The NP and Z proteins of LUJV have been linked to IFN-I response modulation. IRF-3 & NF-κB nuclear translocation can be inhibited by NP, lowering IFN- promoter activity. It may also inhibit RIG-I function & inhibit IFN-β generation. Z protein interacts directly with RIG-I and MDA-5, limiting their interaction with downstream signaling pathways & inhibiting NF-κB & IRF-3 activation.
Lujo virus (LUJV) infection causes Lujo hemorrhagic fever (LUHF), characterized by manifestations like severe Lassa fever caused by another arenavirus. The onset of the illness is sudden, with nonspecific symptoms such as fever, malaise, headache, and muscle pain. Additional symptoms follow it, including sore throat, nausea, vomiting, non-bloody diarrhea, and variable retrosternal or epigastric pain.
During the first week of illness, a distinctive rash appears on the torso and limbs. The rash is blanching, erythematous, and maculopapular, spreading across the body but sparing the palms and soles. Facial swelling with subconjunctival hemorrhage is also commonly observed.
Neurologic signs tend to occur later in the disease course, including tremors, seizures, and cerebral edema. Hepatosplenomegaly, or enlargement of the liver and spleen, may develop. While significant bleeding is not typically seen, subconjunctival hemorrhages, palatal ecchymoses, and bleeding at injection sites may occur.
The disease rapidly progresses to multiorgan failure and shock in the second week of illness. Disseminated intravascular coagulopathy may be present, characterized by abnormal blood clotting and bleeding. Neurological complications can also manifest in the later stages of the disease.
The case fatality rate of Lujo virus infection is extremely high, ranging from 80% to 100%. Most deaths occur within a mean of 9 days from the onset of symptoms, although the survivor may experience a prolonged recovery.
A series of laboratory tests on blood samples, liver biopsies, & skin pinch biopsies from patients 3 and 2 were used to diagnose the Lujo virus. Initially, the National Institute for Communicable Disease (NICD-NHLS) in Johannesburg performed reverse transcription-polymerase chain reaction (RT-PCR), antigen detection enzyme-linked immunosorbent tests (ELISA), and antibody detection ELISA.
These assays detect known agents of African viral hemorrhagic fevers, such as the Lassa Fever Virus and other arenaviruses from the Old World (OW). All tests, however, had negative results.
To further study the cases, liver and skin biopsy samples were collected from the patients at the NICD’s biosafety level four facility. While these biopsies were tested in South Africa, tissues were shipped to the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, and to Columbia University in New York. The University of the Witwatersrand’s Department of Anatomical Pathology found histopathological results confirming viral hemorrhagic fever in liver & skin biopsies.
Immunohistochemical staining: It detects Lujo virus antigens in tissue samples like liver and skin biopsies. Monoclonal antibodies, for example, are broadly cross-reactive with Old World arenaviruses, including the Lujo virus.
This antibody binds selectively to Lujo virus antigens found in tissue sections. The antibody is frequently labeled with a visible marker, like an enzyme or fluorescent dye, so the stained spots may be seen under a microscope. The appearance and distribution of Lujo virus antigens in tissue slices can be recognized by staining, confirming the existence of Lujo virus infection.
Antibody Detection ELISA: This test detects the presence of antibodies produced by the patient’s immune system in response to the Lujo virus infection. It can identify IgM antibodies, indicating recent or acute infection, or IgG antibodies, indicating past or previous infection.
Genetic Sequencing: In-depth genetic sequencing techniques, such as 454-pyrosequencing, can be employed to determine the complete genome sequence of the Lujo virus. It provides valuable information about the virus’s genetic makeup, allowing for further characterization and comparison with related viruses.
Preventing exposure to rodents and their excrement, implementing infection control practices in healthcare settings.
Early diagnosis and treatment may improve outcomes. Ribavirin has been used, but its efficacy is uncertain. Other potential treatments being explored include statins, N-acetylcysteine, and recombinant factor VIIa, but more research is needed to confirm their effectiveness.
Currently, there is no specific vaccine for the Lujo virus. Some studies have identified potential Lujo virus entry inhibitors, which may lead to vaccine development. Drugs such as trametinib, manidipine, and lercanidipine have shown potential as inhibitors, but further studies are required to evaluate their antiviral activity and mode of action in vivo.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
